Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab With or Without SBRT in Advanced Merkel Cell Carcinoma
NCT03304639Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2018
- Primary completion
- Jun 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in Merkel cell carcinoma (MCC), sponsored by National Cancer Institute. Started Jun 2018; status: completed.
02
Drugs
03
Conditions
Merkel cell carcinoma (MCC)
Beyond the preview
Go deeper on NCT03304639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03304639.